A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Overexpression of β-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA–IIA Squamous Cell Lung Cancer Irrespective.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004 Tomohiko.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD

Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer Kyohei Masai, MD, Hiroyuki Sakurai,

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience Tsuguo Naruke,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Postoperative Prognosis in Patients with Non-small Cell Lung Cancer According to the Method of Initial Detection Takeshi Hanagiri, MD, PhD, Kenji Sugio,

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database Tetsuya Mizuno, MD, Meinoshin.

Frank Detterbeck, MD Journal of Thoracic Oncology

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Combined Resection of Superior Vena Cava for Lung Carcinoma: Prognostic Significance of Patterns of Superior Vena Cava Invasion Kenji Suzuki, MD, Hisao.

Lung Cancer with Localized Ground-Glass Attenuation Represents Early-Stage Adenocarcinoma in Nonsmokers Nobuhiko Seki, MD, Shigeki Sawada, MD, Masao.

Prognostic Factors Based on Clinicopathological Data Among the Patients with Resected Peripheral Squamous Cell Carcinomas of the Lung Tomonari Kinoshita,

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions Hisao Asamura, MD, Kenji Suzuki,

Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002 Noriyoshi Sawabata, MD,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Skip Mediastinal Nodal Metastases in the IIIa/N2 Non-Small Cell Lung Cancer Nenad Ilic, MD, PhD, Ante Petricevic, MD, PhD, Dragan Arar, MD, Slavica Kotarac,

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Histological Scoring for Small Lung Adenocarcinomas 2 cm or Less in Diameter: A Reliable Prognostic Indicator Akiko Miyagi Maeshima, MD, Naobumi Tochigi,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non- small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Validation of the Proposed International Association for the Study of Lung Cancer Non- small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival: Its Implications for the Forthcoming TNM Staging Based on a Large-Scale.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi- Institutional Retrospective Study Using a Propensity Score Analysis

Carcinoma of the esophagus: Prognostic significance of histologic type

Ethnic Differences in the Management of Lung Cancer in New Zealand

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Primary Small Cell Carcinoma of the Esophagus

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in 2004: Demographic and Prognosis Changes Over Decade Noriyoshi Sawabata, MD, PhD, Etsuo.

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Visceral Pleural Invasion Classification in Non–Small-Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer:

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori Sohara, MD, Kenji Eguchi, MD, Masaki Mori, MD, Yohichi Nakanishi, MD, Ryosuke Tsuchiya, MD, Kaoru Shimokata, MD, Hiroshi Inoue, MD, Toshihiro Nukiwa, MD, Etsuo Miyaoka, MD Journal of Thoracic Oncology Volume 3, Issue 1, Pages 46-52 (January 2008) DOI: 10.1097/JTO.0b013e31815e8577 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A survival curve for all histologic types and all stages (n = 13,010). The 5-year survival rate for the entire group is 61.4%. Journal of Thoracic Oncology 2008 3, 46-52DOI: (10.1097/JTO.0b013e31815e8577) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Survival curves according to histologic type. The 5-year survival rates according to histologic type are as follows: 67.3% for adenocarcinoma (n = 8239), 52.5% for squamous cell carcinoma (n = 3700), 48.1% for small cell carcinoma (n = 390), 45.5% for large cell carcinoma (n = 474), and 42.1% for adenosquamous carcinoma (n = 207). There is a significant difference in survival between adenocarcinoma and others (p = 0.0000). AD, adenocarcinoma; SQ, squamous cell carcinoma; SM, small cell carcinoma; LG, large cell carcinoma; AS, adenosquamous carcinoma. Journal of Thoracic Oncology 2008 3, 46-52DOI: (10.1097/JTO.0b013e31815e8577) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Survival curves according to gender. The 5-year survival rates of female (n = 4228) and male (n = 8664) patients are 74.1% and 55.2%, respectively. The survival of female patients is significantly better than that of male patients (p = 0.0000). Journal of Thoracic Oncology 2008 3, 46-52DOI: (10.1097/JTO.0b013e31815e8577) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Survival curves of small cell lung carcinoma cancers according to c-stage (A) and p-stage (B) (n = 390). The 5-year survival rates by c-stage are as follows: 58.8% for IA (n = 161), 58.0% for IB (n = 77), 47.1% for IIA (n = 17), 25.3% for IIB (n = 38), 29.0% for IIIA (n = 61), 36.3% for IIIB (n = 19), and 27.8% for IV (n = 12). The 5-year survival rates by p-stage are as follows: 58.3% for IA (n = 127), 60.2% for IB (n = 79), 40.6% for IIA (n = 29), 41.1% for IIB (n = 29), 28.3% for IIIA (n = 60), 34.6% for IIIB (n = 40), and 30.8% for IV (n = 13). Journal of Thoracic Oncology 2008 3, 46-52DOI: (10.1097/JTO.0b013e31815e8577) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Survival curves of non-small cell histologies according to c-stage (A) and p-stage (B) (n = 12,620). The 5-year survival rates by c-stage are as follows: 77.3% for IA (n = 5642), 59.8% for IB (n = 3081), 54.1% for IIA (n = 205), 43.9% for IIB (n = 1227), 38.3% for IIIA (n = 1628), 32.6% for IIIB (n = 526), and 26.5% for IV (n = 198). The 5-year survival rates by p-stage are as follows: 83.9% for IA (n = 4772), 66.3% for IB (n = 2629), 61.0% for IIA (n = 361), 47.4% for IIB (n = 1330), 32.8% for IIIA (n = 1862), 29.6% for IIIB (n = 1108), and 23.1% for IV (n = 375). Journal of Thoracic Oncology 2008 3, 46-52DOI: (10.1097/JTO.0b013e31815e8577) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Survival curves according age in non-small lung cancer. The 5-year survival rates for the three age groups, <50 years (n = 797), ≥50 years but <70 years (n = 6563), and ≥70 years (n = 5147) are 69.9%, 66.0%, and 54.9%, respectively. Journal of Thoracic Oncology 2008 3, 46-52DOI: (10.1097/JTO.0b013e31815e8577) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Distribution of histologic types in 1994 and 1999. Adenocarcinoma increases 7% (from 56% to 63%) and squamous cell carcinoma decreases 5% (from 33% to 28%). Journal of Thoracic Oncology 2008 3, 46-52DOI: (10.1097/JTO.0b013e31815e8577) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 8 Distribution of c-stage (A) and p-stage (B) for non-small cell lung histologies in 1994 and 1999. The percentage of stage I increased from 60 to 69% (11%) in the c-setting, and from 52 to 59% (7%) in the p-setting. Journal of Thoracic Oncology 2008 3, 46-52DOI: (10.1097/JTO.0b013e31815e8577) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions